Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Bio Green Med Solution, Inc. Director's Dealing 2019

Jan 7, 2019

35092_dirs_2019-01-07_506cbebe-7a2e-4cb5-b60f-763f17247691.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cyclacel Pharmaceuticals, Inc. (CYCC)
CIK: 0001130166
Period of Report: 2019-01-03

Reporting Person: Chiao Judy (V.P., Clin. Dev. & Reg. Aff)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-01-04 Option $0.71 A 284592 Acquired 2029-01-04 Common Stock (284592) Direct
2019-01-03 Option $1.74 A 11068 Acquired 2027-12-29 Common Stock (11068) Direct
2019-01-03 Option $1.56 A 10183 Acquired 2028-02-22 Common Stock (10183) Direct

Footnotes

F1: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis.

F2: These securities were granted as part of the Issuer's annual compensation review to executive officers.

F3: On December 29, 2017, Judy Chiao was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 11,068 shares.

F4: On February 22, 2018, Judy Chiao was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 10,183 shares.